Figure 4. Therapeutic vaccination against h5T4 is modestly protective in B16.h5T4 melanoma tumour model.

C57BL/6 mice were challenged subcutaneously with 0.5*10⁶ B16.h5T4 cells and immunised intramuscularly on the same day with 10⁷ IU of ChAdOx1.h5T4 or 10⁶ pfu of MVA.h5T4. One week post challenge/prime, the two groups of mice were injected intramuscularly with 10⁶ pfu of MVA.h5T4. Control mice were challenged but left unvaccinated (naïve). Tumour size was measured three times per week and volumes were calculated as described above. (A) Tumour growth kinetics for each group expressed by mean tumour volume ± SEM. (B) assessment of vaccine efficacy by area under the curve (AUC) analysis at day 12 post B16.h5T4 cell inoculation. (C) Kaplan-Meyer survival curves of the three groups of mice. Bars represent median. Representative data of three biological replicate experiments are shown.